Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 4 of 4 publications.

Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S187. doi: 10.1016/j.jval.2023.03.1013

Zhang K, Huang SP, Touchette D, Marko-Holguin M, Van Voorhees B. Cost-effectiveness of web-based depression programs for adolescents. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Suppl 2):S227. doi: 10.1016/j.jval.2019.04.1055

Harrigan (Zhang) K, Walton SM, Huang SP, Kumar VM, Chapman RH, Atlas SJ, Agboola FO, Ollendorf DA, Touchette DR. Long-term cost effectiveness of valbenazine and deutetrabenazine for tardive dyskinesia. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S184. doi: 10.1016/j.jval.2018.04.1257